Search Results - "Kinch, Michael"

An analysis of FDA-approved drugs: natural products and their derivatives by Patridge, Eric, Gareiss, Peter, Kinch, Michael S., Hoyer, Denton

“…•Natural products contribute more than one-third of all FDA-approved NMEs.•The absolute number of natural product approvals peaked in the 1990s and has since…”
Get full text

WANTED DEAD OR ALIVE: New Thinking to Incentivize Drug Development by Kinch, Michael S.

“…Despite unprecedented advancements in our understanding of disease process and targeting opportunities, our continued ability to discover and develop new…”
Get full text

Fiduciary responsibility by Kinch, Michael S.

Get full text

The pharmaceutical innovator’s dilemma by Kinch, Michael S.

“…•Fast-follower drugs remain popular amongst pharmaceutical executives.•The attraction of fast-follower drugs runs contrary to other industries, where…”
Get full text

Keeping apace on the pharmaceutical treadmill by Kinch, Michael S

“…•A “pharmaceutical treadmill” presents an ever growing challenge for innovators.•High anticipated revenues Mounjaro presents both a blessing and curse for Eli…”
Get full text

Monoclonal antibodies: Trends in therapeutic success and commercial focus by Kinch, Michael S., Kraft, Zachary, Schwartz, Tyler

“…•More than 100 new experimental antibodies now enter into development each year.•Half of experimental monoclonal antibodies and a third of approvals are…”
Get full text

An analysis of FDA-approved drugs for oncology by Kinch, Michael S.

“…•New approvals for cancer have increased dramatically since 1990.•Biotechnology takes the dominant role in early-stage development, whereas pharmaceutical…”
Get full text

The Future of Infrared; III–Vs or HgCdTe? by Kinch, Michael A.

“…For reasons associated with size, weight, power consumption, and cost, the future of infrared systems for all spectral bands is being driven towards megapixel…”
Get full text

Antibiotic Development: Lessons from the Past and Future Opportunities by Kinch, Michael S., Kraft, Zachary, Schwartz, Tyler

“…The challenge of antimicrobial resistance is broadly appreciated by the clinical and scientific communities. To assess progress in the development of medical…”
Get full text

2023 in review: FDA approvals of new medicines by Kinch, Michael S, Kraft, Zachary, Schwartz, Tyler

“…•2023 tied with 1996 as the year with the greatest number of new entities approved by the FDA.•Cancers have long been dominant as the target for new medicines,…”
Get full text

2022 in review: FDA approvals of new medicines by Kinch, Michael S., Kraft, Zachary, Schwartz, Tyler

“…•The forty-four approvals by FDA in 2022 fell below recent rates but is within the long-term average.•Approvals for orphan indications captured more than half…”
Get full text

2021 in review: FDA approvals of new medicines by Kinch, Michael S., Kraft, Zachary, Schwartz, Tyler

“…•The sixty NME approvals by FDA in 2021 was tied for the highest in post-PDUFA history.•NMEs approved for orphan indications or with an expedited or priority…”
Get full text

An overview of FDA-approved new molecular entities: 1827–2013 by Kinch, Michael S., Haynesworth, Austin, Kinch, Sarah L., Hoyer, Denton

“…•1453 new molecular entities (NMEs) approved as therapeutics in the USA.•As a consequence of consolidation, ten companies control more than two-thirds of all…”
Get full text

Immunoconjugates and bispecific antibodies: Trends in therapeutic success and commercial focus by Kinch, Michael S., Kraft, Zachary, Schwartz, Tyler

“…•Immunoconjugates and bispecific antibodies are rapidly gainin in popularity.•Most immunoconjugates and bsAbs are developed for the treatment of cancer.•A…”
Get full text

Sources of innovation for new medicines: questions of sustainability by Kinch, Michael S., Kraft, Zachary, Schwartz, Tyler

“…•Company formation peaked in the early 2000s, declining after the 2008 downturn.•Company departures (mergers, bankruptcies & quitting research) have steadily…”
Get full text

2020 in review: FDA approvals of new medicines by Kinch, Michael S., Kraft, Zachary, Schwartz, Tyler

“…•Despite a disruptive pandemic, the FDA approved 55 NMEs in 2020, the third highest rate ever.•Orphan approvals surged to capture 60% of NMEs approved in…”
Get full text

An analysis of FDA-approved drugs for neurological disorders by Kinch, Michael S.

“…•A low rate of approvals is observed with bursts in activity in the 1950s and 1990s.•Ion-channel- and GPCR-based targets consistently dominate the field.•The…”
Get full text

An overview of FDA-approved biologics medicines by Kinch, Michael S.

“…•Biologics approvals grew from the early 1980s through 2010, stabilizing thereafter.•Three different disease categories capture more than 70% of initial…”
Get full text

An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs by Kinch, Michael S., Patridge, Eric

“…•New approvals for HIV have decreased dramatically since 2000.•Organizations focused on development of new HIV drugs have comparably declined.•The time (and…”
Get full text

2019 in review: FDA approvals of new medicines by Kinch, Michael S., Kraft, Zachary, Schwartz, Tyler

“…•The FDA approved 53 NMEs in 2019, below the prior year but higher than the five year average.•The use of the Orphan Drug Act shrank by a third, both in…”
Get full text